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Objective: A subset of patients with multiple sclerosis (MS) smoke cannabis to relieve symptoms including spas-
ticity and pain. Recent evidence suggests that smoking cannabis further impairs cognition in peoplewithMS and
is linked to impaired functional brain changes. No such association, however, has been reported between canna-
bis use and structural brain changes, hence the focus of the present study.
Methods: Twenty patients with MS who smoke cannabis for symptom relief, and 19 matched non-cannabis-
smoking MS patients were given the Brief Repeatable Neuropsychological Battery and structural MRI scans. Im-
ageswere segmented into graymatter andwhitematter, and subsequently analysedwith Partial Least Squares, a
data-driven multivariate technique that explores brain–behaviour associations.
Results: In both groups, the Partial Least Squares analysis yielded signiﬁcant correlations between cognitive
scores and both graymatter (33% variance, p b .0001) andwhitematter (17% variance, p b .05) volume. Graymat-
ter volume in the thalamus, basal ganglia, medial temporal, andmedial prefrontal regions, andwhitematter vol-
ume in the fornix correlatedwith cognitive deﬁcits. Crucially, the analysis indicated that brain volume reductions
were associated with more extensive cognitive impairment in the cannabis versus the non-cannabis MS group.
Interpretation: These results suggest that cannabis use inMS results inmore widespread cognitive deﬁcits, which
correlate with tissue volume in subcortical, medial temporal, and prefrontal regions. These are the ﬁrst ﬁndings
demonstrating an association between cannabis use, cognitive impairment and structural brain changes in MS
patients.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cognitive impairment occurs in approximately 40–60% of patients
withmultiple sclerosis (MS), and is associatedwith structural and func-
tional brain changes (Hulst et al., 2013; Lansley et al., 2013). Approxi-
mately 14–18% of MS patients use cannabis for symptomatic relief
from pain, spasticity and insomnia (Chong et al., 2006; Page et al.,
2003). Evidence for enduring effects of cannabis on cognition and cere-
bral integrity in non-MS samples is equivocal, with negative studies off-
set by others revealing deﬁcits in episodic memory, attention, and
executive functioning (Crane et al., 2013), gray matter atrophy in the
hippocampus and basal ganglia (Battaglini et al., 2012), and decreased
white matter integrity in hippocampal efferent connections (Zalesky
et al., 2012). Given the effects of MS on the brain, patients who smoke
cannabis may be particularly vulnerable to similar cerebral changes
and associated cognitive deﬁcits.brook Health Sciences Centre,
M5, Canada. Tel.: +1 416 480
ero).
. This is an open access article underRecent evidence conﬁrms this: MS patients who smoke cannabis
show further deterioration in processing speed, memory, and executive
functioning (Ghaffar and Feinstein, 2008; Honarmand et al., 2011).
Moreover, cannabis use is linked to less-efﬁcient recruitment of brain
regions during a workingmemory task (Pavisian et al., 2014). However,
noMRI data to date show a speciﬁc association between structural brain
changes and cognitive deﬁcits in MS patients who smoke cannabis
(Pavisian et al., 2014). Whether this reﬂects the absence of structural
change or the limitations of the MRI analyses is unclear. Given the dif-
fuse nature of MS-related cerebral pathology, and the wide distribution
of cannabis receptors in the brain, it is possible that multivariate analy-
ses may uncover underlying effects not observable using standard uni-
variate approaches. To this end, the present study explored whether
there is a structural basis for the cognitive differences present between
MS patients who smoke cannabis and those who do not.
2. Materials and methods
2.1. Subjects
Details of patient recruitment and the descriptive data for this sam-
ple have been reported previously (Pavisian et al., 2014) and arethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nosis of MS were recruited fromMS clinics. A diagnosis of MS was con-
ﬁrmed according to modiﬁed McDonald criteria (McDonald et al.,
2001). Of these 39 subjects, 20 smoked cannabis on a regular basis
(i.e. daily use, n = 17; 4–5 times/week, n = 2; 2–3 times/week, n =
1). With respect to the reason for use, 14/20 patients smoked cannabis
for relief of physical symptoms, 2/20 for recreational purposes, and 4/
20 smoked cannabis for both medicinal and recreational purposes. In
terms of disease course, in the cannabis-smoking group 16/20 patients
had relapsing–remitting, 2/20 patients had primary progressive, and
2/20 patients had secondary progressive MS. In the non-cannabis
group, 17/19 patients had relapsing–remitting, 1/19 patients had pri-
mary progressive, and 1/19 patients had secondary progressive MS.
Cannabis use was conﬁrmed with a positive urine test for metabolites
(a composite of THCCOOH glucuronide and THC-COOH). Twelve hours
prior to testing, patients were asked to refrain from using cannabis in
order to prevent any behavioural effects of acute intoxication. To ensure
compliance, saliva samples were collected prior to testing to screen for
Δ9-tetrahydrocannabinol (THC) use within the last 4–6 h (NarcoCheck).
The 19 MS patients who had never used cannabis were matched to the
cannabis group on all demographic and disease-related variables. All sub-
jects in the non-cannabis group had negative urine and saliva tests.
2.2. Clinical variables
Age, sex, handedness, years of education, employment status,
disease-related variables, and Expanded Disability Status Scale scores
were obtained at the time of testing. Visual acuity was measured via
Snellen chart. Estimates of premorbid IQ were obtained via the
Wechsler Test of Adult Reading. All patients were given the Brief Repeat-
able Battery of Neuropsychological Tests (BRNB) in MS (Rao, 1990),
consisting of tests measuring verbal memory (Selective Reminding Test;
SRT) visual memory (10/36 Spatial Recall Test) processing speed (Paced
Auditory Serial Addition Test; PASAT, 2 and 3 s; Symbol Digit Modalities
Test; SDMT), and verbal ﬂuency (Word List Generation; WLG). Mood
and anxiety symptoms were measured using the Hospital Anxiety and
Depression Scale (HADS) (Zigmond and Snaith, 1983), using a cut-off
score of 8 or greater to denote clinically signiﬁcant anxiety or depression,
respectively (Honarmand and Feinstein, 2009). The modiﬁed fatigue im-
pact scale was given to record subjective fatigue (Fisk et al., 1994).
2.3. Image acquisition
MRIs were collected on a 3 T MRI scanner (GE Healthcare, Milwau-
kee, WI) using an 8-channel head coil. T1-weighted anatomical scans
(repetition time [TR] = 8.1 ms, echo time [TE] = 3.2, ﬂip angle 5 8°,
ﬁeld of view [FOV] = 22 cm, 190 slices, slice thickness = 1 mm), PD/T2
scans (TR = 2500 ms, TE = 11.1/90, ﬂip angle = 90°, FOV = 22 cm, 48
slices, slice thickness = 3 mm), and FLAIR images (TR = 9700 ms,
TE=140, FOV=22 cm, 48 slices, slice thickness=3mm)were acquired
for each subject. In addition, functionalMRI scanswere also acquired dur-
ing a working memory task (n-back), as well as diffusion tensor imaging
scans, which are reported elsewhere (Pavisian et al., 2014).
2.4. Imaging analysis
Images were preprocessed using SPM8, VBM8, and the Lesion Seg-
mentation Toolbox (LST) (Schmidt et al., 2012), using standard settings.
This process included ﬁrst quantifying and subsequently ﬁlling WM le-
sions in order to limit segmentation error caused by thepresence ofWM
lesions (Magon et al., 2014). After lesion ﬁlling, brain tissue was seg-
mented and normalized to a common template space for voxel-wise
testing. LST uses a lesion growth algorithm that considers information
from T1 and FLAIR images simultaneously to identify white matter le-
sions. For the LST settings, a threshold value of κ = 0.2 was chosen
and conﬁrmed by visual inspection by a board-certiﬁed neurologistwith expertise in MS, as a setting that captured the majority of white
matter lesions without including non-lesion tissue in the calculation of
overall lesion volume. Following identiﬁcation, the resultant lesion tis-
sue was quantiﬁed, and subsequently ﬁlled, using the average white
matter intensity for each subject. This ensured an accurate estimate of
gray matter (GM) volume, and that our analysis included only healthy
tissue. Filled T1 images were then segmented via VBM8 using default
parameters: images were co-registered using linear and non-linear
transformations, and tissue segmented without tissue priors, using
partial volume estimation. Segmented GM and WM images were nor-
malized using high-resolution afﬁne registration and the non-linear
DARTEL algorithm to the DARTEL template provided with VBM8, in
MNI space. Images were resampled to a resolution of 1.5 mm3 voxels
and smoothedwith an8mmfull-widthhalf-maximumGaussian kernel.
Preprocessed GM and WM images were entered into a behavioural
Partial Least Squares (PLS) analysis (Krishnan et al., 2011; McIntosh
and Lobaugh, 2004). Generally, PLS is a data-driven, multivariate tech-
nique that ﬁnds independent latent variables which maximize the co-
variance between two sets of data via singular value decomposition. It
has been used to characterize brain–behaviour associations in other pa-
tient groups where structural brain changes are more subtle, such as
mild traumatic brain injury (Levine et al., 2013), and autism (Ecker
et al., 2012).
Speciﬁcally, we employed behavioural PLS, which searches for latent
variables that maximize the covariance between brain data (GM and
WM voxels) and neuropsychological test scores. This analysis deter-
mines whether there exist patterns of regional brain volume change
that are correlated with neuropsychological test scores and how these
correlations may be similar or different across patient groups. Such an
analysis would allow us to determine a) if regional GM and/orWM vol-
ume is associated with cognitive performance within each patient
group, b) which brain regions and cognitive tests are correlated, and
c) whether the pattern of those correlations differ between cannabis
and non-cannabis groups. For this analysis, raw total scores from all 5
neuropsychological tests (SRT — total learning score across trials; 10/
36— total learning score across trials;WLG— total # ofwords generated
across trials; SDMT — total correct; PASAT-2 — total correct) were en-
tered simultaneously, each as individual variables of interest. We used
raw scores as both groups were well-matched in terms of age, level of
education, and estimated IQ.
The statistical signiﬁcance of extracted variables was evaluated by
1000permutation tests, using samplingwithout replacement. The robust-
ness (i.e. salience) of each brain region3s contribution to the latent vari-
able is determined through bootstrap resampling that resampled the
data 500 times with replacement to estimate the standard error of the
weight of each voxel on the latent variable. Brain regionswere considered
reliable if they had a ratio of weight to standard error (i.e. bootstrap ratio,
equivalent to a z-score) greater than 4.5, corresponding to a probability of
p b 0.0001. Because the mathematical procedure is completed in a single
step, there is no need for correcting for multiple comparisons.
Furthermore, we also segmented T1-weighted images using
Freesurfer to obtain subcortical GMvolumes, to conduct ancillary region
of interest analyses. Speciﬁcally, wewere interested in the thalamus and
hippocampus, based on recent evidence demonstrating atrophy in these
regions due to MS (Benedict et al., 2013; Pardini et al., 2014).
2.5. Ethics
All subjects provided informed consent prior to participation. In ad-
dition, the study was approved by the research ethics board at
Sunnybrook Health Sciences Centre.
3. Results
There were no signiﬁcant differences between the cannabis and non-
cannabis groups in terms of age (cannabis M = 41.30, non-cannabis
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non-cannabis M = 15.20, t = −1.5, p = 0.14), or IQ (cannabis M =
110.85, non-cannabis M = 110.57, t = 0.97, p = 0.92). In addition,
there were no differences in disease duration (cannabis M= 9.50, non-
cannabis M= 9.90, t=−0.79, p=0.44), disability severity (EDSS; can-
nabis M= 2.83, non-cannabis M= 2.47, t=−0.62, p=0.54), or mood
symptoms (HADS-anxiety, cannabis #= 13, non-cannabis #= 11, χ2 =
0.21, p=0.65; HADS-depression, cannabis #= 11, non-cannabis #= 8,
χ2 = 0.85, p= 0.42). However, the cannabis group showed signiﬁcantly
poorer performance on tests of spatial memory (10/36 recall; cannabis
M= 16.40, non-cannabis M= 20.79 t =−2.29, p=0.03) and informa-
tion processing speed (PASAT 2 s; cannabis M = 28.35, non-cannabis
M = 39.47, t =−2.41, p = 0.03). There were no differences between
groups in terms of total GM, WM, or lesion volume (Table 1).
The behavioural PLS analysis extracted two latent variables that
showed a signiﬁcant association between tissue volume and cognition,
accounting for 50% of the overall covariance. The ﬁrst latent variable
(p b 0.0001) represented the association between GM volume and cog-
nitive performance (33% of the variance). Brain regions where GM was
signiﬁcantly correlated with cognitive performance included the thala-
mus and basal ganglia, medial temporal regions (hippocampus, amyg-
dala, and fusiform gyrus), lateral temporal cortex, posterior parietal
lobes, and both the lateral and medial prefrontal cortex (Fig. 1;
Table 2). Crucially, the non-cannabis and cannabis groups showed dif-
ferential patterns of brain–behaviour correlations: In the non-cannabis
group, GM volume in the aforementioned regions was associated only
with tests of processing speed (i.e. SDMT, PASAT-2), and WLG, a test
of executive control that is timed and thus has a speeded component.
However, in the cannabis group, GM volume was associated with per-
formance onmeasures of processing speed (SDMT, PASAT-2) and verbal
memory (SRT).
The second latent variable (17% of the variance, p b 0.05) represent-
ed the association between WM volume and cognitive performance,
and showed a similar pattern of results: in the non-cannabis group,
WM volume correlated with tests where processing speed contributes
to task performance (SDMT, PASAT, WLG) whereas in the cannabis
group, WM volume correlated with all ﬁve cognitive measures, includ-
ing both verbal (SRT) and visual memory (10/36 recall) (Fig. 2). Regions
of white matter correlating with cognition included the fornix continu-
ing into the left ﬁmbria, as well as WM in superior parietal and middle
frontal regions (Table 3). Collectively, these results provide robust evi-
dence to suggest that in cannabis-smoking patients, GM and WM vol-
ume reduction is associated in more widespread cognitive deﬁcits.
As the PLS analysis revealed a signiﬁcant correlation between sub-
cortical GM and memory in the cannabis group but not the non-
cannabis group, we ran additional region of interest analyses to test
whether these correlations were signiﬁcantly higher in the cannabis
group, versus the non-cannabis group. Speciﬁcally, as the analysis iden-
tiﬁed left hippocampal involvement in cognitive performance, we com-
puted correlations between verbalmemory scores and left hippocampal
volumes obtained via Freesurfer. There was a signiﬁcant correlation be-
tween left hippocampal volume and verbal memory in the cannabis
group (r= .52, p= .02), but not in the non-cannabis group (r=−.03,
p = .90). Moreover, the magnitude of the correlation was signiﬁcantlyTable 1
Estimates of total graymatter, whitematter, and lesion volume inMS patientswho do and
do not smoke cannabis.
MS cannabis MS non-cannabis t-Test/χ2 p value
n = 20 n = 19
M (SD) M (SD)
Total brain tissue volume (mL)
Gray matter 680.37 (76.50) 675.18 (52.38) −0.25 0.81
White matter 514.26 (71.52) 493.76 (50.41) −1.03 0.31
Lesion 25.87 (21.19) 18.52 (21.82) −1.04 0.31larger in cannabis group compared to the non-cannabis group (Fisher
Zdifference = 1.73, p= .04, 1-tailed), suggesting that cannabis use moder-
ated the association between cognition and hippocampal volume. As a
comparison, we also calculated correlations between left thalamic vol-
umes and processing speed performance (SDMT) in both groups, given
recent evidence suggesting the importance of the thalamus in cognitive
deﬁcits in MS, and given the SDMT is the most sensitive measure of cog-
nitive performance in these patients (Benedict et al., 2013; Stober et al.,
2009). There was a signiﬁcant correlation between thalamic volume
and processing speed in the cannabis (r = .58, p = .01) and non-
cannabis groups (r = .48, p = .04): however, these correlations were
not signiﬁcantly higher in the cannabis group (Fisher Zdifference = .39,
p= .35, 1-tailed) (Fig. 3).
4. Discussion
To our knowledge, this is the ﬁrst study in MS patients demonstrat-
ing a link between structural brain changes and cognitive deﬁcits due to
smoking cannabis. GM andWM volume in medial and lateral temporal
regions, thalamus, basal ganglia, and prefrontal cortex was associated
with more widespread cognitive deﬁcits in cannabis-smoking MS pa-
tients, compared to patients who were cannabis-naïve. Speciﬁcally, de-
creased regional brain volumewas associatedwith poorer performance
on all neuropsychological tests in MS patients who smoked cannabis,
whereas only speeded tasks correlated with brain volumes in non-
cannabis patients. Moreover, verbal memory was signiﬁcantly correlat-
ed with hippocampal volume in the cannabis group, but not the non-
cannabis group, and cannabis-smoking MS patients also showed
signiﬁcantly lower performance on the 10/36 spatial recall test and
the PASAT.
Taken together, this pattern of results raises the intriguing notion
that MS patients who smoke cannabis may be less able to compensate
for declines in memory, due to regional volume reductions. That is,
given there were no group differences in terms of overall brain volume
or subcortical structures, non-cannabis MS patients may be able to uti-
lize other strategies to compensate to a degree for their memory, but
not their processing speed deﬁcits. Conversely, cannabis-smoking MS
patients, who show signiﬁcantly lower processing speed and visual
memory scores, appear no longer able to compensate for either, and
thus lower regional brain volumes in these patients was associated
with poorer scores on all cognitive tests. These results complement
the fMRI data elicited from the same sample of patients reported previ-
ously (Pavisian et al., 2014), which revealed an increased and more an-
atomically diffuse pattern of cerebral activation during a working
memory task in the cannabis group. Crucially, these functional and
structural imaging ﬁndings cannot be explained by differences in demo-
graphic factors such as premorbid intelligence, disease severity, or in
terms of differences in global measures of lesion, GM, or WM volumes
as these were not signiﬁcantly different between the two MS groups.
Given the absence of previous imaging studies in cannabis smoking
MS patients, a review of data from non-MS samples is helpful in placing
the current results in context. Notably, earlier systematic reviews pro-
vided mixed evidence linking structural brain changes to cannabis use
in non-psychotic subjects (Martin-Santos et al., 2010). However, more
recent studies are revealing a different picture. For example, Zalesky
et al. (2012) found that efferent hippocampal connections (i.e. fornix,
ﬁmbria) and white matter tracts in the corpus callosum were impaired
in chronic cannabis users, with axonal integrity correlatingwith the age
of onset for smoking cannabis. A meta-analysis of structural brain
changes in healthy, long-term users concluded that selective brain re-
gions such as the hippocampus were particularly vulnerable to atrophy
(Rocchetti et al., 2013). Furthermore, a systematic review of 43 studies
involving chronic cannabis users and matched control subjects who
were non-users reported similar results, namely selective atrophy of
medial prefrontal cortices and the cerebellum in the cannabis group
(Batalla et al., 2013). A subsequent review conﬁrmed these ﬁndings,
Fig. 1. Pattern of whole brain covariance of gray matter changes with neuropsychological test scores in MS patients who do or do not smoke cannabis.
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regions to the deleterious effects of cannabis (Lorenzetti et al., 2014).
These imaging data are in turn helpful in explaining some of the
cognitive ﬁndings to emerge from studies looking at long-term, non-
psychotic cannabis smokers. As with the earlier structural neuroimag-
ing data, initial ﬁndings were equivocal, with greater certainty regard-
ing the adverse acute effects of Δ9-THC — one of the main cannabis
metabolites — on verbal and working memory, but less clarity on
whether the deﬁcits endure beyond the period of intoxication
(Schoeler and Bhattacharyya, 2013). A recent longitudinal study sug-
gested that impairment may continue particularly if cannabis use
started as an adolescent and continued for years. Of particular concern
is the ﬁnding that in a situation such as this, multifocal cognitive deﬁcits
can persist even after cannabis cessation (Meier et al., 2012). While
these conclusion have been called into question because of a failure to
control for socio-economic status (Rogeberg, 2013), it is germane tonote that recent ﬁndings of cognitive impairment in non-clinical sam-
ples of cannabis smokers (Thames et al., 2014), and a pattern of gender
speciﬁc cognitive deﬁcits (greater memory difﬁculties in females, more
executive challenges inmales) (Crane et al., 2013), ﬁt with the structur-
al brain MRI ﬁndings of selective hippocampal and prefrontal cortex at-
rophy. Moreover, in a recent systematic review, Batalla et al. (2013)
noted a link between hippocampal volume and memory performance
in cannabis users (Batalla et al., 2013). This region may be particularly
sensitive to the effects of cannabis given its high concentration of
endocannabinoid receptors (Glass et al., 1997; Herkenham et al., 1990).
The results from our MS sample dovetail with the ﬁndings summa-
rized above. Notably, the regions that showed structural changes with
cannabis use in the general population are the same as those associated
with cognitive impairment in the present study. Speciﬁcally, we found
correlations betweenGMvolume in the hippocampus and poorermem-
ory performance only in cannabis users. Furthermore, we found that
Table 2
Graymatter regions showing a signiﬁcant correlationwith neuropsychological test performance across subjects in both patient groups. A positive bootstrap ratio (BSR) denotes a positive
correlation between graymatter volume and cognitive test performance. BSRs are the ratio of a voxels weight divided by the bootstrap-derived standard error, and are equivalent to a z-score.
Coordinates and BSRs are listed for the peak voxel of each cluster.
Region Cluster size (voxels) X Y Z BSR
Frontal
L Inferior frontal gyrus 113 −48 45 1.5 6.50
R Inferior frontal gyrus 23 34.5 36 −18 4.97
R Middle frontal gyrus 127 48 48 12 6.35
R Superior frontal gyrus 92 21 45 34.5 5.66
L Superior frontal gyrus 27 −22.5 40.5 39 4.91
R Medial frontal cortex 133 12 −1.5 61.5 6.00
L Medial frontal cortex 136 −7.5 −19.5 52.5 5.58
L Anterior cingulate cortex 1127 −4.5 28.5 27 7.64
R Anterior cingulate cortex 21 10.5 27 28.5 4.80
R Orbitofrontal cortex 182 1.5 22.5 −10.5 5.95
R Frontopolar cortex 87 34.5 60 −1.5 5.42
L Middle cingulate cortex 283 −4.5 −30 42 5.51
Parietal
L Inferior parietal lobe 334 −51 −30 46.5 6.97
L Inferior parietal lobe 53 −55.5 −70.5 13.5 4.92
R Inferior parietal lobe 45 51 −57 49.5 5.73
L Supramarginal gyrus 257 −60 −48 27 9.90
L Superior parietal lobule 212 −21 −55.5 52.5 6.23
R Superior parietal lobule 137 33 −39 39 6.87
R Angular gyrus 234 55.5 −57 28.5 6.55
R Precuneus 93 1.5 −51 39 5.11
L Posterior cingulate cortex 735 −13.5 −46.5 19.5 −6.71
R Posterior cingulate cortex 609 13.5 −43.5 21 −6.69
R Paracentral lobule 646 10.5 −42 73.5 6.48
L Precentral gyrus 841 −18 −13.5 73.5 7.54
R Precentral gyrus 24 28.5 −28.5 70.5 4.99
R Postcentral gyrus 203 55.5 −15 43.5 6.93
R Postcentral gyrus 297 45 −31.5 52.5 6.73
R Postcentral gyrus 75 21 −21 55.5 5.60
L Postcentral gyrus 222 −49.5 −18 49.5 5.81
Temporal
L Superior temporal gyrus 413 −54 −21 9 6.80
R Inferior temporal gyrus 74 45 −37.5 −16.5 6.54
L Hippocampus 30 −27 −12 −15 4.95
L Amygdala 27 −12 −10.5 −16.5 4.81
R Fusiform gyrus 294 40.5 −13.5 −36 5.94
Occipital
L Lingual gyrus 32 −30 −58.5 −1.5 −5.72
L Lingual gyrus 42 −24 −78 0 −6.79
Other
R Insula 3881 37.5 0 −19.5 10.41
L Putamen 7444 −18 7.5 −6 7.91
L Cerebellum 209 −15 −82.5 −21 5.20
R Caudate 51 13.5 10.5 15 5.14
BSR = bootstrap ratio.
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more widespread cognitive deﬁcits in cannabis-smoking MS patients,
the sameWM tracts affected by long-term cannabis use in non-MS pa-
tients (Zalesky et al., 2012). Taken together, these results suggest that
the hippocampus and its associatedWM tracts are particularly vulnera-
ble in MS patients who use cannabis.
Our ﬁndings are also consistent with cerebral atrophy due to MS-
related pathology. It is now well-established that GM atrophy reliably
occurs in the thalamus and putamen,with brain changes robustly linked
to cognitive deﬁcits (Benedict et al., 2013) and more extensive neuro-
logical disability (Riccitelli et al., 2012). Hippocampal atrophy also oc-
curs to some extent in MS, and is associated with memory deﬁcits
(Pardini et al., 2014; Sicotte et al., 2008). Indeed, both patient groups
showed signiﬁcant correlations between thalamic volumes and tests
of information processing speed. Interestingly, we found that GM vol-
ume reductions in the default-mode network (DMN; i.e. lateral tempo-
ral regions, precuneus, lateral parietal cortices, and medial prefrontal
cortex) (Andrews-Hanna, 2012) was also correlated with poorer cogni-
tive performance. Although the overall relevance of the DMN in MS re-
quires further study, there is evidence that resting activity in this
network predicts memory performance in MS patients (Sumowskiet al., 2013). Furthermore, MS patients who are cognitively-impaired
show decreased connectivity between DMN structures, compared to
cognitively-intact MS patients (Louapre et al., 2014). Based on our ﬁnd-
ings that regional volume reductions in the DMN is associated with
more widespread cognitive deﬁcits in cannabis-smoking MS patients,
one may posit that DMN integrity is necessary to mount any functional
compensation for cognitive deﬁcits, and thus volume loss in these re-
gions would be associated with more global cognitive decline. This
point is emphasized by the results of a study showing that in a sample
of MS patients who received cognitive rehabilitation, the extent of func-
tional connectivity within the DMNwas predictive of lasting treatment
gains (Parisi et al., 2014).
In arriving at our conclusionswe are conscious that a relatively small
sample may have obscured any subtle group differences in volume be-
tween the cannabis and non-cannabis groups. In addition, the lack of a
matched healthy control group precluded our ability to determine
whether patients3 brains showed cerebral atrophy, relative to healthy
brains. Nevertheless, we present evidence demonstrating the adverse
effects of cannabis use on both GM and WM in MS: for patients who
smoke cannabis, decreased GM and WM volume is associated with a
wider array of cognitive deﬁcits beyond that explained by MS alone.
Fig. 2. Pattern of whole brain covariance of white matter changes with neuropsychological test scores in MS patients who do or do not smoke cannabis.
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symptom relief must be weighed against the negative impact on brain
health and cognition, the full extent of which is only beginning to
emerge. The ﬁndings also raise the intriguing question of what amount
of cannabis use is required before such effectsmanifest, or whether cog-
nitive deﬁcits are reversible with cessation of cannabis use. Data from
the general population suggest that this may be the case (Schreiner
and Dunn, 2012). Whether this also holds true in MS subjects given
the imaging data presented heremust be questionable, but nevertheless
worthy of future study.Author contributions
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